An active pharmaceutical ingredient (API) is a drug or a combination of drugs used in finished pharmaceutical products (FPP) intended for the diagnosis, treatment, or prevention of diseases. API is the component of any drug that produces the intended effects. Some drugs, such as combination therapies, have multiple active ingredients to treat different symptoms or act in different ways. Production of APIs has conventionally been done by pharmaceutical companies in their home countries; however, in recent years, many companies have chosen to send manufacturing overseas with an aim to cut costs. This has caused major changes in how these drugs are regulated, with more stringent guidelines and inspections put into place.
360Quadrants, the most granular comparison platform, has released a quadrant on the Active Pharmaceutical Ingredient Market to help businesses make quicker and more informed decisions. The quadrant has Pfizer, Roche, and Sanofi sharing space as Visionary Leaders. 360Quadrants are generated Active Pharmaceutical Ingredient company analysis Like product maturity and company maturity. Quadrants will be updated every three months based on market and regional analyses and developments in the Active Pharmaceutical Ingredient Market. 360Quadrants also lists the 20 best companies in the Active Pharmaceutical Ingredient Market space.
categorization of Active pharmaceutical ingredient (api) vendors on 360QUADRANTs
30+ companies offering Active Pharmaceutical Ingredients were analyzed, of which 20 companies were shortlisted and categorized on a quadrant under Visionary Leaders, Innovators, Dynamic Differentiators, and Emerging Leaders.
Pfizer, Roche, Sanofi, Novartis, AbbVie, GlaxoSmithKline, Gilead Sciences, Merck & Co, Eli Lilly, Johnson & Johnson, AstraZeneca, Celgene, and Boehringer Ingelheim have been identified as Visionary Leaders,as they have established product portfolios and a robust market presence &business strategy.
Teva, Allergen, Amgen, and Bristol-Myers Squibb have been identified as Innovators, as they have focused product portfolios but mediocre business strategies.
Novo Nordisk, Mylan, and Biogen Idec have been recognized as Dynamic Differentiators, as they have strong business strategies but weaker product offerings as compared to other market players. These companies are known to focus on specific product offerings, as opposed to having elaborate portfolios.
Takeda, Daiichi Sankyo, Shire, and Astellas have been identified as Emerging Companies, as they have niche product offerings but poor business strategies.
360Quadrants conducts an in-depth SWOT analysis and accurately analyzes the companies considered for evaluation. This helps service providers learn about new opportunities and areas where they lag behind their peers. It also helps clients choose the most appropriate vendors for their requirements.
360Quadrants company evaluation Methodology
The top Active Pharmaceutical Ingredient Competitive evaluation performed using the following methodology:
360Quadrants is the largest marketplace looking to disrupt US $6.3 trillion of technology spends and is the only rating platform for vendors in the technology space. The platform provides users access to unbiased information that helps them make qualified business decisions. The platform facilitates deeper insight using direct engagement with 650+ industry experts and analysts and allows buyers to discuss their requirements with 7500 vendors. Companies get to win ideal new customers, customize their quadrants, decide key parameters, and position themselves strategically in a niche space, to be consumed by giants and startups alike. Experts get to grow their brand and increase their thought leadership. The platform targets the building of a social network that links industry experts with companies worldwide. The platform has around 400 total buyers across various markets.
360Quadrants will also be launching quadrants in fields like Digital Transformation Software, Cloud Computing Software, and Access Control Software.